Market overview
The global vaccine cryoprotectants market is worth USD 81 mn in 2026 and is forecast to reach USD 176 mn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Trehalose and sucrose is the largest by type segment.
| Scope | Protective excipients added to vaccines for freezing, drying and storage: trehalose, sucrose, glycerol, DMSO, amino acids and polymers sold to vaccine makers. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 75 mn |
| Value 2026 | USD 81 mn |
| Value 2036 | USD 176 mn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 645 tonnes |
| Volume 2036 | 1,260 tonnes |
| Average price 2026 | USD 126,200 per tonne |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Vaccine Cryoprotectants market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 81 mn |
| 2027 | USD 88 mn |
| 2028 | USD 95 mn |
| 2029 | USD 103 mn |
| 2030 | USD 111 mn |
| 2031 | USD 120 mn |
| 2032 | USD 129 mn |
| 2033 | USD 139 mn |
| 2034 | USD 151 mn |
| 2035 | USD 163 mn |
| 2036 | USD 176 mn |
Vaccine Cryoprotectants market segmentation
By type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Trehalose and sucrose | 44.0% | 43.2% | USD 36 mn | 7.8% |
| Glycerol and DMSO | 24.0% | 21.5% | USD 20 mn | 6.8% |
| Amino acids and polymers | 20.0% | 23.6% | USD 16 mn | 9.8% |
| Other excipients | 12.0% | 11.8% | USD 9.8 mn | 7.8% |
By vaccine type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| mRNA and lipid nanoparticle | 28.0% | 34.8% | USD 23 mn | 10.4% |
| Live attenuated | 26.0% | 22.4% | USD 21 mn | 6.4% |
| Viral vector | 18.0% | 18.7% | USD 15 mn | 8.4% |
| Protein subunit and others | 28.0% | 24.1% | USD 23 mn | 6.4% |
By function
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Lyoprotectants | 42.0% | 40.0% | USD 34 mn | 7.5% |
| Cryoprotectants for frozen storage | 34.0% | 34.0% | USD 28 mn | 8.0% |
| Stabiliser for liquid formulations | 24.0% | 26.0% | USD 20 mn | 8.9% |
By grade
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| GMP pharma grade | 60.0% | 64.0% | USD 49 mn | 8.7% |
| Research grade | 28.0% | 24.0% | USD 23 mn | 6.3% |
| Animal-free grade | 12.0% | 12.0% | USD 9.8 mn | 8.0% |
By buyer
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Vaccine manufacturers | 56.0% | 52.0% | USD 46 mn | 7.2% |
| CDMOs | 24.0% | 26.0% | USD 20 mn | 8.9% |
| Biotech | 20.0% | 22.0% | USD 16 mn | 9.0% |
Top 25 countries for vaccine cryoprotectants by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 88.0% of 2026 revenue and the 25 countries below together hold 96.4%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 24 mn | 30.0% | USD 50 mn | 7.5% |
| 2 | China | USD 12 mn | 15.0% | USD 32 mn | 10.0% |
| 3 | Germany | USD 6.5 mn | 8.0% | USD 13 mn | 7.0% |
| 4 | India | USD 6.5 mn | 8.0% | USD 17 mn | 10.0% |
| 5 | Japan | USD 5.7 mn | 7.0% | USD 11 mn | 6.5% |
| 6 | Belgium | USD 4.1 mn | 5.0% | USD 8.1 mn | 7.1% |
| 7 | France | USD 4.1 mn | 5.0% | USD 8.1 mn | 7.1% |
| 8 | United Kingdom | USD 3.3 mn | 4.0% | USD 6.5 mn | 7.2% |
| 9 | Switzerland | USD 2.4 mn | 3.0% | USD 4.7 mn | 6.9% |
| 10 | South Korea | USD 2.4 mn | 3.0% | USD 5.8 mn | 9.0% |
| 11 | Spain | USD 1.5 mn | 1.9% | USD 2.9 mn | 6.5% |
| 12 | Canada | USD 0.90 mn | 1.1% | USD 1.7 mn | 6.5% |
| 13 | Netherlands | USD 0.67 mn | 0.8% | USD 1.2 mn | 6.5% |
| 14 | Australia | USD 0.54 mn | 0.7% | USD 1.0 mn | 6.4% |
| 15 | Mexico | USD 0.46 mn | 0.6% | USD 1.2 mn | 10.3% |
| 16 | Brazil | USD 0.40 mn | 0.5% | USD 1.1 mn | 10.2% |
| 17 | Singapore | USD 0.35 mn | 0.4% | USD 0.95 mn | 10.5% |
| 18 | Turkey | USD 0.32 mn | 0.4% | USD 0.86 mn | 10.5% |
| 19 | Denmark | USD 0.29 mn | 0.4% | USD 0.54 mn | 6.4% |
| 20 | Ireland | USD 0.27 mn | 0.3% | USD 0.51 mn | 6.6% |
| 21 | Russia | USD 0.25 mn | 0.3% | USD 0.47 mn | 6.5% |
| 22 | Taiwan | USD 0.24 mn | 0.3% | USD 0.44 mn | 6.4% |
| 23 | Thailand | USD 0.22 mn | 0.3% | USD 0.60 mn | 10.5% |
| 24 | Indonesia | USD 0.21 mn | 0.3% | USD 0.56 mn | 10.3% |
| 25 | Poland | USD 0.20 mn | 0.2% | USD 0.53 mn | 10.0% |
| Rest of world | USD 2.9 mn | 3.6% | USD 5.5 mn | 6.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Merck KGaA
- Croda
- Pfanstiehl
Group 2: Regional and specialist players
- Hayashibara
- Roquette
- Avantor
- Gaylord Chemical
- BioLife Solutions
- Spectrum Chemical
- Emery Oleochemicals
Group 3: Emerging and niche players
- Nagase
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the vaccine cryoprotectants market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by type, by vaccine type, by function, by grade, by buyer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the vaccine cryoprotectants market?
The global vaccine cryoprotectants market is estimated at USD 75 mn in 2025 and USD 81 mn in 2026.
How fast will the vaccine cryoprotectants market grow?
It is forecast to reach USD 176 mn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 94 mn.
Which country is the largest market for vaccine cryoprotectants?
United States is the largest market by revenue at USD 24 mn in 2026, 30.0% of the global total. The three largest countries together hold 53.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 10.0% a year from 2026 to 2036.
Which vaccine cryoprotectants segment is largest?
In the by type split, Trehalose and sucrose is the largest segment with 44.0% of 2026 revenue.
Who are the leading vaccine cryoprotectants companies?
Global leaders include Merck KGaA, Croda, Pfanstiehl.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Federated Learning HealthcareUSD 78 mn · 22.0% CAGR
- Lacrimal DevicesUSD 87 mn · 5.0% CAGR
- AI Osteoporosis Screening ToolsUSD 74 mn · 18.0% CAGR
- Aquaculture Fungal Infection TreatmentUSD 90 mn · 6.0% CAGR
- Emergency Transfer Vacuum MattressUSD 74 mn · 5.0% CAGR
- Ophthalmic Gas DeliveryUSD 74 mn · 4.8% CAGR
- Dual Lumen ECMO CatheterUSD 73 mn · 8.5% CAGR
- Bioabsorbable StentsUSD 92 mn · 7.0% CAGR